E. Paul Wileyto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
E. Paul Wileyto has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
Caryn Lerman
University of Pennsylvania
3 shared publicationsFreda Patterson
From University of Pennsylvania, Philadelphia, Pennsylvania, and Massachusetts General Hospital, Boston, Massachusetts
3 shared publications- Larry W. Hawk
Department of Psychology, University at Buffalo
3 shared publications Leonard H. Epstein
State University of New York at Buffalo
3 shared publications- Caryn Lerman
University of Pennsylvania
2 shared publications Richard A. Brown
Brown University
2 shared publications
Latest Publications
- Open Access
- 1 December 2017
- Published by Elsevier in Addictive Behaviors
- Vol. 75, 122-129
Measures and predictors of varenicline adherence in the treatment of nicotine dependence
- 1 December 2017
- Published by Elsevier in Addictive Behaviors
- Vol. 75, 122-129
Open AccessMeasures and predictors of varenicline adherence in the treatment of nicotine dependence
- Open Access
- 8 May 2017
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 127 (6) , 2378-2391
Long-lived keratin 15+ esophageal progenitor cells contribute to homeostasis and regeneration
The esophageal lumen is lined by a stratified squamous epithelium comprised of proliferative basal cells that differentiate while migrating toward the luminal surface and eventually desquamate. Rapid epithelial renewal occurs, but the specific cell of origin that supports this high proliferative demand remains unknown. Herein, we have described a long-lived progenitor cell population in the mouse esophageal epithelium that is characterized by expression of keratin 15 (Krt15). Genetic in vivo lineage tracing revealed that the Krt15 promoter marks a long-lived basal cell population able to self-renew, proliferate, and generate differentiated cells, consistent with a progenitor/stem cell population. Transcriptional profiling demonstrated that Krt15+ basal cells are molecularly distinct from Krt15– basal cells. Depletion of Krt15-derived cells resulted in decreased proliferation, thereby leading to atrophy of the esophageal epithelium. Further, Krt15+ cells were radioresistant and contributed to esophageal epithelial regeneration following radiation-induced injury. These results establish the presence of a long-lived and indispensable Krt15+ progenitor cell population that provides additional perspective on esophageal epithelial biology and the widely prevalent diseases that afflict this epithelium.
- 8 May 2017
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 127 (6) , 2378-2391
Open AccessLong-lived keratin 15+ esophageal progenitor cells contribute to homeostasis and regeneration
The esophageal lumen is lined by a stratified squamous epithelium comprised of proliferative basal cells that differentiate while migrating toward the luminal surface and eventually desquamate. Rapid epithelial renewal occurs, but the specific cell of origin that supports this high proliferative demand remains unknown. Herein, we have described a long-lived progenitor cell population in the mouse esophageal epithelium that is characterized by expression of keratin 15 (Krt15). Genetic in vivo lineage tracing revealed that the Krt15 promoter marks a long-lived basal cell population able to self-renew, proliferate, and generate differentiated cells, consistent with a progenitor/stem cell population. Transcriptional profiling demonstrated that Krt15+ basal cells are molecularly distinct from Krt15– basal cells. Depletion of Krt15-derived cells resulted in decreased proliferation, thereby leading to atrophy of the esophageal epithelium. Further, Krt15+ cells were radioresistant and contributed to esophageal epithelial regeneration following radiation-induced injury. These results establish the presence of a long-lived and indispensable Krt15+ progenitor cell population that provides additional perspective on esophageal epithelial biology and the widely prevalent diseases that afflict this epithelium.
- 2 February 2010
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 152 (3) , 144-151
Effectiveness of Extended-Duration Transdermal Nicotine Therapy
Schnoll and associates assessed whether extended-duration transdermal nicotine therapy (21 mg for 24 weeks) increased abstinence from tobacco more than standard-duration therapy (21 mg for 8 weeks)... Background: Tobacco dependence is a chronic, relapsing condition that may require extended treatment. Objective: To assess whether extended-duration transdermal nicotine therapy increases abstinenc...
- 2 February 2010
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 152 (3) , 144-151
Effectiveness of Extended-Duration Transdermal Nicotine Therapy
Schnoll and associates assessed whether extended-duration transdermal nicotine therapy (21 mg for 24 weeks) increased abstinence from tobacco more than standard-duration therapy (21 mg for 8 weeks)... Background: Tobacco dependence is a chronic, relapsing condition that may require extended treatment. Objective: To assess whether extended-duration transdermal nicotine therapy increases abstinenc...
- 31 January 2006
- Published by Elsevier in Addictive Behaviors
- Vol. 31 (9) , 1670-1682
Maternal smoking during late pregnancy and offspring smoking behaviour
- 31 January 2006
- Published by Elsevier in Addictive Behaviors
- Vol. 31 (9) , 1670-1682
Maternal smoking during late pregnancy and offspring smoking behaviour
- 1 April 2005
- Published by Oxford University Press (OUP) in Nicotine & Tobacco Research
- Vol. 7 (2) , 257-268
Recurrent event analysis of lapse and recovery in a smoking cessation clinical trial using bupropion
We report a reanalysis of data from a prior study describing the event history of quitting smoking aided by bupropion, using recurrent-event models to determine the effect of the drug on occurrence of lapses and recoveries from lapse (resumption of abstinence). Data were collected on 1,070 subjects across two similar double-blind randomized clinical trials of bupropion versus placebo and fitted with separate Cox regression models for lapse and recovery. Analyses were split using discrete time-varying covariates between the treatment (weeks 1–10) and follow-up phases (end of treatment to 12 months). Bupropion was associated with slower lapse during treatment for both sexes, and being female was associated with faster lapse across both phases. Drug did not affect time to recovery for males but was associated with faster recovery among females, allowing women to recover as quickly as men. High levels of nicotine dependence did not affect time to lapse but were associated with slower recovery from lapse across treatment and follow-up phases. During the treatment phase, higher levels of baseline depression symptoms had no effect on time to lapse but were associated with slower recovery from lapse. Results highlight the asymmetry in factors preventing lapse versus promoting recovery. Specifically, dependence, depression symptoms, and a sex×drug interaction were found to affect recovery but not lapse. Further research disentangling lapse and recovery events from summary abstinence measures is needed to help us develop interventions that take advantage of bupropion at its best and that compensate where it is weak.
- 1 April 2005
- Published by Oxford University Press (OUP) in Nicotine & Tobacco Research
- Vol. 7 (2) , 257-268
Recurrent event analysis of lapse and recovery in a smoking cessation clinical trial using bupropion
We report a reanalysis of data from a prior study describing the event history of quitting smoking aided by bupropion, using recurrent-event models to determine the effect of the drug on occurrence of lapses and recoveries from lapse (resumption of abstinence). Data were collected on 1,070 subjects across two similar double-blind randomized clinical trials of bupropion versus placebo and fitted with separate Cox regression models for lapse and recovery. Analyses were split using discrete time-varying covariates between the treatment (weeks 1–10) and follow-up phases (end of treatment to 12 months). Bupropion was associated with slower lapse during treatment for both sexes, and being female was associated with faster lapse across both phases. Drug did not affect time to recovery for males but was associated with faster recovery among females, allowing women to recover as quickly as men. High levels of nicotine dependence did not affect time to lapse but were associated with slower recovery from lapse across treatment and follow-up phases. During the treatment phase, higher levels of baseline depression symptoms had no effect on time to lapse but were associated with slower recovery from lapse. Results highlight the asymmetry in factors preventing lapse versus promoting recovery. Specifically, dependence, depression symptoms, and a sex×drug interaction were found to affect recovery but not lapse. Further research disentangling lapse and recovery events from summary abstinence measures is needed to help us develop interventions that take advantage of bupropion at its best and that compensate where it is weak.
- 1 April 2004
- Published by Oxford University Press (OUP) in Nicotine & Tobacco Research
- Vol. 6 (2) , 357-366
Do small lapses predict relapse to smoking behavior under bupropion treatment?
Although bupropion is known to be an effective aid to smoking cessation, little is known about its mode of action. In the present study we tested the hypothesis that bupropion reduces the likelihood that a smoking lapse, or slip, leads to a subsequent relapse. This hypothesis was tested in the context of a clinical trial of bupropion as a smoking cessation aid, using Cox regression and representing lapse history as a discrete time-varying covariate. Bupropion treatment reduced the probability of relapse during the treatment phase (hazard ratio, or HR=.421, p≤.000) but not during the follow-up phase (end of treatment to 6 months, HR=.896, p≤.67). As anticipated, having small lapses during treatment contributed to or predicted subsequent relapse, both during treatment (HR=2.897, p≤.000) and during follow-up (HR=2.320, p≤.008). Although an interaction was found between drug treatment and lapse history in predicting subsequent failure during the treatment phase, the finding suggested that drug slightly increased the effect of lapse on eventual failure during treatment (HR=1.706, p≤.012). No evidence was found that the effect of this interaction carried forward into follow-up (HR=1.500, p≤.30). Although the mechanisms of action of bupropion may best be addressed in a human laboratory study, results from this clinical trial suggest that the effectiveness of bupropion treatment is not attributable to reducing the effect of a lapse in predicting relapse.
- 1 April 2004
- Published by Oxford University Press (OUP) in Nicotine & Tobacco Research
- Vol. 6 (2) , 357-366
Do small lapses predict relapse to smoking behavior under bupropion treatment?
Although bupropion is known to be an effective aid to smoking cessation, little is known about its mode of action. In the present study we tested the hypothesis that bupropion reduces the likelihood that a smoking lapse, or slip, leads to a subsequent relapse. This hypothesis was tested in the context of a clinical trial of bupropion as a smoking cessation aid, using Cox regression and representing lapse history as a discrete time-varying covariate. Bupropion treatment reduced the probability of relapse during the treatment phase (hazard ratio, or HR=.421, p≤.000) but not during the follow-up phase (end of treatment to 6 months, HR=.896, p≤.67). As anticipated, having small lapses during treatment contributed to or predicted subsequent relapse, both during treatment (HR=2.897, p≤.000) and during follow-up (HR=2.320, p≤.008). Although an interaction was found between drug treatment and lapse history in predicting subsequent failure during the treatment phase, the finding suggested that drug slightly increased the effect of lapse on eventual failure during treatment (HR=1.706, p≤.012). No evidence was found that the effect of this interaction carried forward into follow-up (HR=1.500, p≤.30). Although the mechanisms of action of bupropion may best be addressed in a human laboratory study, results from this clinical trial suggest that the effectiveness of bupropion treatment is not attributable to reducing the effect of a lapse in predicting relapse.
- 1 February 2004
- Published by Springer Nature in Behavior Research Methods, Instruments, & Computers
- Vol. 36 (1) , 41-51
Using logistic regression to estimate delay-discounting functions
The monetary choice questionnaire (MCQ) and similar computer tasks ask preference questions in order to ascertain indifference, the perceived equivalence of immediate versus larger delayed rewards....
- 1 February 2004
- Published by Springer Nature in Behavior Research Methods, Instruments, & Computers
- Vol. 36 (1) , 41-51
Using logistic regression to estimate delay-discounting functions
The monetary choice questionnaire (MCQ) and similar computer tasks ask preference questions in order to ascertain indifference, the perceived equivalence of immediate versus larger delayed rewards....